Summary

Global Hyperuricemia Market was valued at USD 4.56 billion in 2024 and is projected to reach USD 6.71 billion by 2030, expanding at a compound annual growth rate (CAGR) of 6.63% during the forecast period. This market represents a dynamic and evolving segment of the healthcare industry, centered on the diagnosis, treatment, and management of hyperuricemia—an ailment marked by elevated uric acid levels in the bloodstream.
Hyperuricemia is commonly associated with gout, a form of inflammatory arthritis, and is also linked to other medical conditions such as kidney stones and cardiovascular disease. The market has experienced notable growth in recent years, propelled by several key drivers.
Key Market Drivers
Rising Prevalence of Hyperuricemia
The increasing global incidence of hyperuricemia serves as a primary growth catalyst for this market. In the United States alone, approximately 38 million people—over 11% of the population—are affected by this condition. Globally, this trend is being fueled by lifestyle factors such as poor dietary habits, physical inactivity, and the growing prevalence of obesity. Notably, in 2022, over one billion individuals worldwide were classified as obese, a condition strongly correlated with elevated uric acid levels.
This rising prevalence has led to heightened demand for both diagnostic tools and therapeutic solutions. Greater public awareness regarding the health risks posed by hyperuricemia has led to increased medical consultations, encouraging early diagnosis and proactive disease management. Furthermore, the aging global population is another significant contributor, as the risk of hyperuricemia rises with age due to diminished renal function. By 2050, individuals aged 60 and above are expected to constitute 22% of the global population, up from 12% in 2015—further intensifying the need for effective management and treatment strategies.
Key Market Challenges
Lack of Routine Screening
One of the critical challenges facing the hyperuricemia market is the limited implementation of routine screening protocols. Hyperuricemia often progresses silently, with few or no symptoms until it leads to more serious complications such as gout, kidney stones, or cardiovascular disorders. Without routine screening, many individuals remain undiagnosed until the condition reaches an advanced stage, resulting in delayed treatment and elevated healthcare costs.
Routine screening not only enables early detection but also provides an opportunity for patient education and preventive intervention through lifestyle modifications—such as improved diet, weight management, and physical activity. Proactive screening is thus a cost-effective strategy to mitigate long-term health complications and reduce the economic burden on healthcare systems.
Key Market Trends
Focus on Research and Development (R&D)
Innovation through research and development has emerged as a central theme in the evolution of the global hyperuricemia market. With strong correlations between hyperuricemia and other debilitating conditions like gout and cardiovascular disease, the need for advanced therapeutic solutions has intensified.
Pharmaceutical companies and academic research institutions are actively pursuing novel treatment approaches, including gene therapy aimed at modifying the genetic pathways that regulate uric acid metabolism. Such innovations could lead to more effective and precisely targeted interventions.
Another emerging trend is the integration of precision medicine into hyperuricemia management. By leveraging patients’ genetic, biochemical, and lifestyle data, healthcare providers can deliver highly customized treatment plans that enhance efficacy and reduce adverse effects—ultimately improving patient outcomes.
Ongoing research is also deepening the understanding of the biological mechanisms underlying hyperuricemia and its comorbidities. These insights are aiding in the development of more sophisticated diagnostic tools and next-generation therapeutics, thereby driving sustained market growth.
Key Market Players
• Arthrosi Therapeutics, Inc
• Dr. Reddy's Laboratories Ltd.
• Urica Therapeutics, Inc
• Zydus Lifesciences
• Takeda Pharmaceutical Company Limited
• Novartis AG
• Hikma Pharmaceuticals Plc
• Mylan N.V.
• AstraZeneca Plc
• Sun Pharmaceutical Industries Ltd
Report Scope:
In this report, the Global Hyperuricemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Hyperuricemia Market, By Type:
o Primary
o Secondary
• Hyperuricemia Market, By Drug Type:
o Xanthine Oxidase Inhibitors
o Nonsteroidal Anti-Inflammatory Drugs
o Corticosteroids
o Others
• Hyperuricemia Market, By Route of Administration:
o Oral
o Injectable
• Hyperuricemia Market, By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Hyperuricemia Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Hyperuricemia Market.
Available Customizations:
Global Hyperuricemia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Hyperuricemia Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Type (Primary, Secondary)
4.2.2. By Drug Type (Xanthine Oxidase Inhibitors, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Others)
4.2.3. By Route of Administration (Oral, Injectable)
4.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
4.2.5. By Region
4.2.6. By Company (2024)
4.3. Market Map
4.3.1. By Type
4.3.2. By Drug Type
4.3.3. By Route of Administration
4.3.4. By Distribution Channel
4.3.5. By Region
5. Asia Pacific Hyperuricemia Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type
5.2.2. By Drug Type
5.2.3. By Route of Administration
5.2.4. By Distribution Channel
5.2.5. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Hyperuricemia Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Type
5.3.1.2.2. By Drug Type
5.3.1.2.3. By Route of Administration
5.3.1.2.4. By Distribution Channel
5.3.2. India Hyperuricemia Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Type
5.3.2.2.2. By Drug Type
5.3.2.2.3. By Route of Administration
5.3.2.2.4. By Distribution Channel
5.3.3. Australia Hyperuricemia Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Type
5.3.3.2.2. By Drug Type
5.3.3.2.3. By Route of Administration
5.3.3.2.4. By Distribution Channel
5.3.4. Japan Hyperuricemia Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Type
5.3.4.2.2. By Drug Type
5.3.4.2.3. By Route of Administration
5.3.4.2.4. By Distribution Channel
5.3.5. South Korea Hyperuricemia Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Type
5.3.5.2.2. By Drug Type
5.3.5.2.3. By Route of Administration
5.3.5.2.4. By Distribution Channel
6. Europe Hyperuricemia Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Drug Type
6.2.3. By Route of Administration
6.2.4. By Distribution Channel
6.2.5. By Country
6.3. Europe: Country Analysis
6.3.1. France Hyperuricemia Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Drug Type
6.3.1.2.3. By Route of Administration
6.3.1.2.4. By Distribution Channel
6.3.2. Germany Hyperuricemia Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Drug Type
6.3.2.2.3. By Route of Administration
6.3.2.2.4. By Distribution Channel
6.3.3. Spain Hyperuricemia Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Drug Type
6.3.3.2.3. By Route of Administration
6.3.3.2.4. By Distribution Channel
6.3.4. Italy Hyperuricemia Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Type
6.3.4.2.2. By Drug Type
6.3.4.2.3. By Route of Administration
6.3.4.2.4. By Distribution Channel
6.3.5. United Kingdom Hyperuricemia Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Type
6.3.5.2.2. By Drug Type
6.3.5.2.3. By Route of Administration
6.3.5.2.4. By Distribution Channel
7. North America Hyperuricemia Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Type
7.2.2. Type
7.2.3. By Distribution Channel
7.2.4. By Route of Administration
7.2.5. By Country
7.3. North America: Country Analysis
7.3.1. United States Hyperuricemia Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Drug Type
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Distribution Channel
7.3.2. Mexico Hyperuricemia Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Drug Type
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Distribution Channel
7.3.3. Canada Hyperuricemia Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Drug Type
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Distribution Channel
8. South America Hyperuricemia Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Drug Type
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Hyperuricemia Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Drug Type
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Distribution Channel
8.3.2. Argentina Hyperuricemia Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Drug Type
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Distribution Channel
8.3.3. Colombia Hyperuricemia Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Drug Type
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Distribution Channel
9. Middle East and Africa Hyperuricemia Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Drug Type
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.2.5. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Hyperuricemia Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Drug Type
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Distribution Channel
9.3.2. Saudi Arabia Hyperuricemia Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Drug Type
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Distribution Channel
9.3.3. UAE Hyperuricemia Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Drug Type
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Distribution Channel
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. Global Hyperuricemia Market: SWOT Analysis
13. Porter’s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product
14. Competitive Landscape
14.1. Arthrosi Therapeutics, Inc
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Current Capacity Analysis
14.1.5. Financials (In case of listed)
14.1.6. Recent Developments
14.1.7. SWOT Analysis
14.2. Dr. Reddy's Laboratories Ltd.
14.3. Urica Therapeutics, Inc
14.4. Zydus Lifesciences
14.5. Takeda Pharmaceutical Company Limited
14.6. Novartis AG
14.7. Hikma Pharmaceuticals Plc
14.8. Mylan N.V.
14.9. AstraZeneca Plc
14.10.Sun Pharmaceutical Industries Ltd
15. Strategic Recommendations
16. About Us & Disclaimer